Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Malignant Melanoma

  Free Subscription


Articles published in Clin Cancer Res

Retrieve available abstracts of 69 articles:
HTML format
Text format



Single Articles


    March 2019
  1. YAN Y, Wongchenko MJ, Robert C, Larkin J, et al
    Genomic features of exceptional response in vemurafenib +/- cobimetinib-treated patients with BRAFV600-mutated metastatic melanoma.
    Clin Cancer Res. 2019 Mar 1. pii: 1078-0432.CCR-18-0720.
    PubMed     Text format     Abstract available


    February 2019
  2. ZHOU R, Shi C, Tao W, Li J, et al
    Analysis of mucosal melanoma whole-genome landscapes reveals clinically relevant genomic aberrations.
    Clin Cancer Res. 2019 Feb 19. pii: 1078-0432.CCR-18-3442.
    PubMed     Text format     Abstract available


  3. EDWARDS JJ, Tasker A, Silva I, Quek C, et al
    Prevalence and cellular distribution of novel immune checkpoint targets across longitudinal specimens in treatment-naive melanoma: implications for clinical trials.
    Clin Cancer Res. 2019 Feb 18. pii: 1078-0432.CCR-18-4011.
    PubMed     Text format     Abstract available


  4. ATAY C, Kwak T, Lavilla-Alonso S, Donthireddy L, et al
    BRAF targeting sensitizes resistant melanoma to cytotoxic T cells.
    Clin Cancer Res. 2019 Feb 14. pii: 1078-0432.CCR-18-2725.
    PubMed     Text format     Abstract available


    January 2019
  5. GARTRELL RD, Marks DK, Rizk EM, Bogardus M, et al
    Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II-III Melanoma.
    Clin Cancer Res. 2019 Jan 15. pii: 1078-0432.CCR-18-2847.
    PubMed     Text format     Abstract available


  6. PIRES DA SILVA I, Wang KYX, Wilmott JS, Holst J, et al
    Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma.
    Clin Cancer Res. 2019 Jan 10. pii: 1078-0432.CCR-18-1680.
    PubMed     Text format     Abstract available


  7. WONG PF, Wei W, Smithy JW, Acs B, et al
    Multiplex quantitative analysis of tumor-infiltrating lymphocytes and immunotherapy outcome in metastatic melanoma.
    Clin Cancer Res. 2019 Jan 7. pii: 1078-0432.CCR-18-2652.
    PubMed     Text format     Abstract available


    December 2018
  8. VAN MEIR EG, Dong L, You S, Zhang Q, et al
    Arylsulfonamide 64B inhibits hypoxia/HIF-induced expression of c-Met and CXCR4 and reduces primary tumor growth and metastasis of uveal melanoma.
    Clin Cancer Res. 2018 Dec 18. pii: 1078-0432.CCR-18-1368.
    PubMed     Text format     Abstract available


  9. KIM SH, Roszik J, Cho SN, Ogata D, et al
    The COX2 effector microsomal PGE2 synthase-1 is a regulator of immunosuppression in cutaneous melanoma.
    Clin Cancer Res. 2018 Dec 11. pii: 1078-0432.CCR-18-1163.
    PubMed     Text format     Abstract available


  10. JOSEPH RW, Elassaiss-Schaap J, Kefford R, Hwu WJ, et al
    Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab.
    Clin Cancer Res. 2018;24:6098.
    PubMed     Text format    


    November 2018
  11. TARHINI AA, Lee SJ, Li X, Rao UN, et al
    E3611- A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High Dose Interferon-alpha2b in Advanced Melanoma.
    Clin Cancer Res. 2018 Nov 12. pii: 1078-0432.CCR-18-2258.
    PubMed     Text format     Abstract available


  12. LIM SY, Lee JH, Gide TN, Menzies AM, et al
    Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1-based immunotherapy.
    Clin Cancer Res. 2018 Nov 8. pii: 1078-0432.CCR-18-2795.
    PubMed     Text format     Abstract available


    August 2018
  13. WOODS D, Ramakrishnan R, Laino AS, Berglund AE, et al
    Decreased Suppression and Increased Phosphorylated STAT3 in Regulatory T-cells are Associated with Benefit from Adjuvant PD-1 Blockade in Resected Metastatic Melanoma.
    Clin Cancer Res. 2018 Aug 21. pii: 1078-0432.CCR-18-1100.
    PubMed     Text format     Abstract available


  14. GOTTESDIENER LS, O'Connor S, Busam KJ, Won H, et al
    Rates of ERBB2 Alterations Across Melanoma Subtypes and a Complete Response to Trastuzumab Emtansine in an ERBB2-amplified Acral Melanoma.
    Clin Cancer Res. 2018 Aug 9. pii: 1078-0432.CCR-18-1397.
    PubMed     Text format     Abstract available


    July 2018
  15. TOKER A, Nguyen LT, Stone SC, Yang C, et al
    Regulatory T cells in ovarian cancer are characterized by a highly activated phenotype distinct from that in melanoma.
    Clin Cancer Res. 2018 Jul 31. pii: 1078-0432.CCR-18-0554.
    PubMed     Text format     Abstract available


  16. JOHNSON DB, Dahlman KB
    Class matters: Sensitivity of BRAF-mutant melanoma to MAPK inhibition.
    Clin Cancer Res. 2018 Jul 24. pii: 1078-0432.CCR-18-1795.
    PubMed     Text format     Abstract available


  17. JOHNSON DB, Bordeaux JM, Kim JY, Vaupel CA, et al
    Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of anti-PD-1 Therapies in Metastatic Melanoma.
    Clin Cancer Res. 2018 Jul 18. pii: 1078-0432.CCR-18-0309.
    PubMed     Text format     Abstract available


    June 2018
  18. PAWELEC G
    Unexpected benefits of aging for favorable responses to PD-1 blockade in melanoma?
    Clin Cancer Res. 2018 Jun 15. pii: 1078-0432.CCR-18-1475.
    PubMed     Text format     Abstract available


  19. DANKNER M, Lajoie M, Moldoveanu D, Nguyen TT, et al
    Dual MAPK inhibition is an effective therapeutic strategy for a subset of class II BRAF mutant melanoma.
    Clin Cancer Res. 2018 Jun 14. pii: 1078-0432.CCR-17-3384.
    PubMed     Text format     Abstract available


  20. WARNER AB, Postow MA
    Bigger is not always better: Tumor size and prognosis in advanced melanoma.
    Clin Cancer Res. 2018 Jun 14. pii: 1078-0432.CCR-18-1311.
    PubMed     Text format     Abstract available


    May 2018
  21. FORGET MA, Haymaker C, Hess KR, Meng YJ, et al
    Prospective analysis of adoptive TIL therapy in patients with metastatic melanoma: response, impact of anti-CTLA4, and biomarkers to predict clinical outcome.
    Clin Cancer Res. 2018 May 30. pii: 1078-0432.CCR-17-3649.
    PubMed     Text format     Abstract available


  22. BEZROOKOVE V, Nosrati M, Miller JR, de Semir D, et al
    Role of Elevated PHIP Copy Number as a Prognostic and Progression Marker for Cutaneous Melanoma.
    Clin Cancer Res. 2018 May 18. pii: 1078-0432.CCR-18-0791.
    PubMed     Text format     Abstract available


  23. TEH JLF, Aplin AE
    Playing the melanoma endgame.
    Clin Cancer Res. 2018 May 16. pii: 1078-0432.CCR-18-0989.
    PubMed     Text format     Abstract available


    April 2018
  24. JOSEPH RW, Elassaiss-Schaap J, Kefford RF, Hwu WJ, et al
    Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients With Melanoma Treated With Pembrolizumab.
    Clin Cancer Res. 2018 Apr 23. pii: 1078-0432.CCR-17-2386.
    PubMed     Text format     Abstract available


  25. EROGLU Z, Chen YA, Gibney GT, Weber JS, et al
    Combined BRAF and HSP90 inhibition in patients with unresectable BRAF V600E mutant melanoma.
    Clin Cancer Res. 2018 Apr 19. pii: 1078-0432.CCR-18-0565.
    PubMed     Text format     Abstract available


  26. SANLORENZO M, Vujic I, Floris A, Novelli M, et al
    BRAF and MEK inhibitors increase PD1-positive melanoma cells leading to a potential lymphocyte-independent synergism with anti-PD1 antibody.
    Clin Cancer Res. 2018 Apr 12. pii: 1078-0432.CCR-17-1914.
    PubMed     Text format     Abstract available


  27. YANG J, Hamid O, Carvajal RD
    The Need for Neddylation: A Key to Achieving NED in Uveal Melanoma.
    Clin Cancer Res. 2018 Apr 2. pii: 1078-0432.CCR-18-0020.
    PubMed     Text format     Abstract available


    March 2018
  28. EDWARDS J, Wilmott JS, Madore J, Gide TN, et al
    CD103+ tumor-resident CD8+ T cells are associated with improved survival in immunotherapy naive melanoma patients and expand significantly during anti-PD1 treatment.
    Clin Cancer Res. 2018 Mar 29. pii: 1078-0432.CCR-17-2257.
    PubMed     Text format     Abstract available


  29. ZHANG G, Wu LW, Mender I, Barzily-Rokni M, et al
    Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma.
    Clin Cancer Res. 2018 Mar 21. pii: 1078-0432.CCR-17-2773.
    PubMed     Text format     Abstract available


  30. OO ZY, Stevenson AJ, Proctor MA, Daignault SM, et al
    Endogenous replication stress marks melanomas sensitive to CHK1 inhibitors in vivo.
    Clin Cancer Res. 2018 Mar 13. pii: 1078-0432.CCR-17-2701.
    PubMed     Text format     Abstract available


    January 2018
  31. ATKINS MB, Hodi FS, Thompson JA, McDermott D, et al
    Pembrolizumab plus pegylated interferon alfa-2b or ipilimumab for advanced melanoma or renal cell carcinoma: dose-finding results from the phase 1b KEYNOTE-029 study.
    Clin Cancer Res. 2018 Jan 22. pii: 1078-0432.CCR-17-3436.
    PubMed     Text format     Abstract available


    December 2017
  32. JIN Y, Zhang P, Wang Y, Jin B, et al
    Neddylation blockade diminishes hepatic metastasis by dampening cancer stem-like cells and angiogenesis in uveal melanoma.
    Clin Cancer Res. 2017 Dec 12. pii: 1078-0432.CCR-17-1703.
    PubMed     Text format     Abstract available


    November 2017
  33. GIDE TN, Wilmott JS, Scolyer RA, Long GV, et al
    Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma.
    Clin Cancer Res. 2017 Nov 10. pii: clincanres.2267.2017.
    PubMed     Text format     Abstract available


    October 2017
  34. KOSTER BD, van den Hout MFCM, Sluijter BJR, Molenkamp BG, et al
    Local Adjuvant Treatment with Low-Dose CpG-B Offers Durable Protection against Disease Recurrence in Clinical Stage I-II Melanoma: Data from Two Randomized Phase II Trials.
    Clin Cancer Res. 2017;23:5679-5686.
    PubMed     Text format     Abstract available


    September 2017
  35. BARTOLOME RA, Aizpurua C, Jaen M, Torres S, et al
    Monoclonal antibodies directed against cadherin RGD exhibit therapeutic activity against melanoma and colorectal cancer metastasis.
    Clin Cancer Res. 2017 Sep 15. pii: clincanres.1444.2017.
    PubMed     Text format     Abstract available


    August 2017
  36. ENNEN M, Keime C, Gambi G, Kieny A, et al
    MITF-high and MITF-low cells and a novel subpopulation expressing genes of both cell states contribute to intra and inter-tumoral heterogeneity of primary melanoma.
    Clin Cancer Res. 2017 Aug 28. pii: clincanres.0010.2017.
    PubMed     Text format     Abstract available


  37. KONG Y, Sheng X, Wu X, Yan J, et al
    Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma indicate the potential for CDK4/6 Inhibitors in Targeted Therapy.
    Clin Cancer Res. 2017 Aug 22. pii: clincanres.0070.2017.
    PubMed     Text format     Abstract available


  38. KASHANI-SABET M, Nosrati M, Miller J, Sagebiel R, et al
    Prospective Validation of Molecular Prognostic Markers in Cutaneous Melanoma: A Correlative Analysis of E1690.
    Clin Cancer Res. 2017 Aug 8. pii: clincanres.1317.2017.
    PubMed     Text format     Abstract available


    July 2017
  39. NIESSNER H, Sinnberg T, Kosnopfel C, Smalley KSM, et al
    BRAF inhibitors amplify the pro-apoptotic activity of MEK inhibitors by inducing ER stress in NRAS-mutant melanoma.
    Clin Cancer Res. 2017 Jul 19. pii: clincanres.0098.2017.
    PubMed     Text format     Abstract available


  40. KAKAVAND H, Rawson RV, Pupo GM, Yang JYH, et al
    PD-L1 expression and immune escape in melanoma resistanceto MAPK inhibitors.
    Clin Cancer Res. 2017 Jul 19. pii: clincanres.1688.2016.
    PubMed     Text format     Abstract available


  41. BAI X, Kong Y, Chi Z, Sheng X, et al
    MAPK pathway and TERT promoter gene mutation pattern and its prognostic value in melanoma patients a retrospective study of 2793 cases.
    Clin Cancer Res. 2017 Jul 18. pii: clincanres.0980.2017.
    PubMed     Text format     Abstract available


    June 2017
  42. DELORD JP, Robert C, Nyakas M, McArthur GA, et al
    Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma.
    Clin Cancer Res. 2017 Jun 13. pii: clincanres.2923.2016.
    PubMed     Text format     Abstract available


  43. NISHINO M, Giobbie-Hurder A, Manos MP, Bailey N, et al
    Immune-Related Tumor Response Dynamics in Melanoma Patients Treated with Pembrolizumab: Identifying Markers for Clinical Outcome and Treatment Decisions.
    Clin Cancer Res. 2017 Jun 7. doi: 10.1158/1078-0432.CCR-17-0114.
    PubMed     Text format     Abstract available


    May 2017
  44. KULKARNI A, Al-Hraishawi H, Simhadri S, Hirshfield KM, et al
    BRAF fusion as a novel mechanism of acquired resistance to vemurafenib in BRAF V600E mutant melanoma.
    Clin Cancer Res. 2017 May 24. pii: clincanres.0758.2016.
    PubMed     Text format     Abstract available


  45. BUTTERFIELD LH, Zhao F, Lee S, Tarhini AA, et al
    Immune correlates of GM-CSF and melanoma peptide vaccination in a randomized trial for the adjuvant therapy of resected high-risk melanoma (E4697).
    Clin Cancer Res. 2017 May 23. pii: clincanres.3016.2016.
    PubMed     Text format     Abstract available


  46. WONGCHENKO MJ, McArthur GA, Dreno B, Larkin J, et al
    Gene Expression Profiling in BRAF-Mutated Melanoma Reveals Patient Subgroups With Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib.
    Clin Cancer Res. 2017 May 23. pii: clincanres.0172.2017.
    PubMed     Text format     Abstract available


  47. VILAIN RE, Menzies AM, Wilmott JS, Kakavand H, et al
    Dynamic changes in PD-L1 expression and immune infiltrates early during treatment predict response to PD-1 blockade in melanoma.
    Clin Cancer Res. 2017 May 16. pii: clincanres.0698.2016.
    PubMed     Text format     Abstract available


  48. PARKHURST M, Gros A, Pasetto A, Prickett T, et al
    Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression.
    Clin Cancer Res. 2017;23:2491-2505.
    PubMed     Text format     Abstract available


  49. INFANTE JR, Hollebecque A, Postel-Vinay S, Bauer TM, et al
    Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors.
    Clin Cancer Res. 2017;23:2423-2432.
    PubMed     Text format     Abstract available


    April 2017
  50. FRIEDMAN AA, Xia Y, Trippa L, Le LP, et al
    Feasibility of ultra-high-throughput functional screening of melanoma biopsies for discovery of novel cancer drug combinations.
    Clin Cancer Res. 2017 Apr 26. pii: clincanres.3029.2016.
    PubMed     Text format     Abstract available


  51. SUNSHINE JC, Nguyen P, Kaunitz G, Cottrell T, et al
    PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison.
    Clin Cancer Res. 2017 Apr 20. pii: clincanres.1821.2016.
    PubMed     Text format     Abstract available


  52. SEGAL NH, Logan TF, Hodi FS, McDermott D, et al
    Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody.
    Clin Cancer Res. 2017;23:1929-1936.
    PubMed     Text format     Abstract available


  53. IIDA Y, Ciechanover A, Marzese DM, Hata K, et al
    Epigenetic Regulation of KPC1 Ubiquitin Ligase Effects the NF-kappaB Pathway in Melanoma.
    Clin Cancer Res. 2017 Apr 7. pii: clincanres.0146.2017.
    PubMed     Text format     Abstract available


    March 2017

  54. Correction: PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.
    Clin Cancer Res. 2017;23:1361.
    PubMed     Text format    


    February 2017
  55. CHUK MK, Chang JT, Theoret MR, Sampene E, et al
    FDA Approval Summary: Accelerated Approval of Pembrolizumab for Second-Line Treatment of Metastatic Melanoma.
    Clin Cancer Res. 2017 Feb 24. pii: clincanres.0663.2016.
    PubMed     Text format     Abstract available


  56. BEHERA R, Kaur A, Webster MR, Kim S, et al
    Inhibition of age-related therapy resistance in melanoma by rosiglitazone-mediated induction of Klotho.
    Clin Cancer Res. 2017 Feb 23. pii: clincanres.0201.2017.
    PubMed     Text format     Abstract available


  57. EXLEY MA, Friedlander P, Alatrakchi N, Vriend L, et al
    Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: a Phase 1 Clinical Trial.
    Clin Cancer Res. 2017 Feb 13. pii: clincanres.0600.2016.
    PubMed     Text format     Abstract available


  58. BARONE A, Hazarika M, Theoret MR, Mishra-Kalyani P, et al
    FDA Approval Summary: Pembrolizumab for the Treatment of Patients with Unresectable or Metastatic Melanoma.
    Clin Cancer Res. 2017 Feb 8. pii: clincanres.0664.2016.
    PubMed     Text format     Abstract available


    January 2017
  59. DENIGER DC, Kwong ML, Pasetto A, Dudley ME, et al
    A Pilot Trial of the Combination of Vemurafenib with Adoptive Cell Therapy in Patients with Metastatic Melanoma.
    Clin Cancer Res. 2017;23:351-362.
    PubMed     Text format     Abstract available


  60. HAZARIKA M, Chuk MK, Theoret MR, Mushti S, et al
    U.S. FDA Approval Summary: Nivolumab for Treatment of Unresectable or Metastatic Melanoma Following Progression on Ipilimumab.
    Clin Cancer Res. 2017 Jan 13. pii: clincanres.0712.2016.
    PubMed     Text format     Abstract available


  61. BEAVER JA, Theoret MR, Mushti S, He K, et al
    FDA Approval of Nivolumab for the First-Line Treatment of Patients with BRAFV600 Wild-Type Unresectable or Metastatic Melanoma.
    Clin Cancer Res. 2017 Jan 10. pii: clincanres.0714.2016.
    PubMed     Text format     Abstract available


    November 2016
  62. GANNON P, Baumgaertner P, Huber A, Iancu EM, et al
    Rapid and continued T cell differentiation into long-term effector and memory stem cells in vaccinated melanoma patients.
    Clin Cancer Res. 2016 Nov 21. pii: clincanres.1708.2016.
    PubMed     Text format     Abstract available


  63. NAGARAJAN P, Curry JL, Ning J, Piao J, et al
    Tumor thickness and mitotic rate robustly predict melanoma-specific survival in patients with primary vulvar melanoma: A retrospective review of 100 cases.
    Clin Cancer Res. 2016 Nov 18. pii: clincanres.2126.2016.
    PubMed     Text format     Abstract available


  64. SANGIOLO D, Gammaitoni L, Giraudo L, Macagno M, et al
    Cytokine Induced Killer cells kill chemo-surviving melanoma cancer stem cells.
    Clin Cancer Res. 2016 Nov 4. pii: clincanres.1524.2016.
    PubMed     Text format     Abstract available


  65. KHALIL DN, Postow MA, Ibrahim N, Ludwig DL, et al
    An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma.
    Clin Cancer Res. 2016;22:5204-5210.
    PubMed     Text format     Abstract available


    August 2016
  66. WINKLER F, Osswald M, Blaes J, Liao Y, et al
    Impact of blood-brain barrier integrity on tumor growth and therapy response in brain metastases.
    Clin Cancer Res. 2016 Aug 12. pii: clincanres.1327.2016.
    PubMed     Text format     Abstract available


    April 2016
  67. KREPLER C, Xiao M, Sproesser K, Brafford PA, et al
    Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies.
    Clin Cancer Res. 2016;22:1592-602.
    PubMed     Text format     Abstract available


    March 2016
  68. KOHLHAPP FJ, Kaufman HL
    Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy.
    Clin Cancer Res. 2016;22:1048-54.
    PubMed     Text format     Abstract available


    February 2016
  69. CHARYCH DH, Hoch U, Langowski JL, Lee SR, et al
    NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models.
    Clin Cancer Res. 2016;22:680-90.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: